However, there were significantly more granzyme B-positive CD8+ T cells in the tumours treated with PEG2k-Fmoc-NLG(L) or PTX/PEG2k-Fmoc-NLG(L) compared with Taxol-treated tumours (Fig. 6d). The gene discussed is CD8A; the disease is neoplasm.